Pimera Therapeutics Awarded Grant by US Department of Defense to Evaluate PMR-116, a Novel Inhibitor of RNA Polymerase I (Pol I) Transcription, in Patients with Prostate Cancer

/PRNewswire/ -- Pimera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing breakthrough medicines for cancer and other diseases...

Related Keywords

Australia ,Australian ,Mustapha Haddach ,Amy Conrad ,Luc Furic ,Ross Hannan ,Australian National University ,Linkedin ,Department Of Defense ,Dean Research Biomedical ,Cancer Research ,Prostate Cancer Research Program ,Department Of Cancer Biology ,Pimera Therapeutics Inc ,Pimera Therapeutics ,Translational Prostate Cancer Research ,Peter Maccallum Cancer Centre ,Professor Ross Hannan ,Centenary Chair ,Cancer Biology ,Associate Dean Research ,Peter Maccallum Cancer ,Medical Research Acquisition ,Award Number ,Investor Contact ,